We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 28, 2012

Cisplatin-Based Chemo Shows Up Capecitabine in Triple-Negative Disease

Annals of Oncology


Additional Info

Annals of Oncology
Docetaxel-Cisplatin Might Be Superior to Docetaxel-Capecitabine in the First-Line Treatment of Metastatic Triple-Negative Breast Cancer
Ann. Oncol 2012 Dec 05;[EPub Ahead of Print], Y Fan, BH Xu, P Yuan, et al

Further Reading